Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis

Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis

ABSTRACT Long-term macrolide therapy reduces rates of pulmonary exacerbation in bronchiectasis. However, little is known about the potential for macrolide therapy to alter the composition and function of the oropharyngeal commensal microbiota or to increase the carriage of transmissible antimicrobia...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jocelyn M. Choo, Guy C. J. Abell, Rachel Thomson, Lucy Morgan, Grant Waterer, David L. Gordon, Steven L. Taylor, Lex E. X. Leong, Steve L. Wesselingh, Lucy D. Burr, Geraint B. Rogers
Format: article
Langue:EN
Publié: American Society for Microbiology 2018
Sujets:
antibiotic resistance
bronchiectasis
macrolide therapy
oropharyngeal microbiome
Microbiology
QR1-502
Accès en ligne:https://doaj.org/article/9dccb828593f4ef89e2c94eed49f9713
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/9dccb828593f4ef89e2c94eed49f9713

Documents similaires